Skip to main content
Sign In

HTC Newsroom

Bleeding and Clotting Disorder News & Archives

Plant-Based Delivery Platform Improves Hemophilia Treatment & Addresses Inhibitors
plantbased.jpgResearchers at Penn's School of Dental Medicine have developed a method of delivery for factor VIII that promotes tolerance and prevents inhibitor formation. The method also apears to reverse formation of inhibitors over time in testing of mice.
Hemophilia B Treatment Regimen Meets Endpoint in Phase 3 Trial ResearchOrange.jpg

Pfizer Inc. announced positive results of a Phase 3 study comparing a prophylaxis regimen of BeneFIX Coagulation Factor IX (Recombinant) 100 IU/kg once-weekly to on-demand treatment in people with moderately severe hemophilia B.

See full story at

 NHF and McMaster University Collaborate on Guidelines for Hemophilia Care Models

The National Hemophilia Foundation is undertaking a project to develop evidence-based clinical practice guidelines in hemophilia. The NHF will focus on evaluating different care models, including the comprehensive care model of the Hemophilia Treatment Centers with a goal to support patient-centered decision making and optimize hemophilia care for each patient. See full story at

Listen to Dr. Tim Bernard Discuss Pediatric Stroke with CPR's Colorado Matters
Dr. Tim and TrevorOur own Dr. Tim Bernard had the opportunity to discuss pediatric stroke with the popular radio show "Colorado Matters" on Colorado Public Radio. He and the father of one of our patients talk about pediatric stroke, how it affects families and what the HTC research team is doing to discover more. You can listen to the entire interview at (photo: CU School of Medicine)

FDA Approves Longer-Lasting Drug Eloctate For Treatment of Hemophilia A
FDA ApprovalThe Food and Drug Administration has approved Eloctate, a new long-acting drug by Biogen Idec Inc., for the treatment of hemophilia A. The approval comes just two months after the FDA approved Biogen Idec's hemophilia B treatment Alprolix. Full Story at

European Commission Approves Pradaxa for Prevention of DVT and PE
Pradaxa Approved in EUBoehringer Ingelheim announced that Pradaxa (dabigatran etexilate) has been approved by the European Commission for the treatment and prevention of recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE). The U.S. FDA approved Pradaxa earlier this year. Full Story at

Drug Companies Pledge Factor VIII Donation in Developing Countries

BiogenSobiBiogen Idec Inc. and their partner Swedish Orphan Biovitrum AB recently announced that they will donate one billion international units of Factor VIII therapy for humanitarian aid programs. Full Story at and informational video can be found at


Dr. Tim Bernard in Denver Post Article about CU Grant & Research on Pediatric Stroke

TimBernardDenverPost05182014.jpgThe HTC's Dr. Tim Bernard was featured in a recent article in the Denver Post that highlighted the $2.5 million grant that will fund research that is now underway on the effects of strokes on children. Dr. Bernard is one of the experts on the research team studying pediatric stroke. Full Story at (photo: Kathryn Scott Osler, The Denver Post)


The HTC Has Also Joined Twitter! Follow Us and Get Involved!
TwitterThe HTC has joined Twitter and created a profile here: . Any of our patients, families, fellow providers and other interested parties are welcome to follow us and keep up with the latest news, events and information about our center and the disorders we treat.
See our Social Media page for more.

The HTC Has Joined Facebook. Like Our Page and Connect With Us Today!

FacebookThe HTC has joined Facebook by creating a page here:  If Facebook is a social media tool our patients and families use, we hope they will connect with us and keep up with the latest news, events and information about our center, hemophilia, bleeding and clotting disorders and pediatric stroke. See our Social Media page here. 

New Findings in Study Support Less Frequent Dosing for Hemophilia B Patients

ResearchCSL Behring presented findings at the World Federation of Hemophilia 2014 that supported less frequent dosing in Hemophilia B patients treated with coagulation factor IX with recombinant Albumin (rIX-FP). The study is ongoing and changes in this treatment for Hemophilia B patients has not been approved in the United States. Full Story at 

FDA Approves Kogenate FS for Adults with Hemophilia A

FDA ApprovalBayer HealthCare announced that the U.S. Food and Drug Administration has approved a new indication for Bayer's Kogenate FS antihemophilic factor VIII (recombinant) based on data from a study headed by Marilyn Manco-Johnson, M.D. at the University of Colorado Hemophilia and Thrombosis Center at Anschutz Medical Campus. Full Story at

Baxter Announces FDA Approval of ADVATE with BAXJECT III Reconstitution System

FDA ApprovalBaxter International announced on April 23, 2014 that the U.S. Food and Drug Administration has approved a new reconstitution system for ADVATE (Antihemophilic Factor [Recombinant]). ADVATE and the diluent come pre-packaged in the new BAXJECT III reconstitution system.


88% of Previous Relapsers Achieve Hepatitis C Cure with Simeprevir-based Triple Therapy

Hepatitis C CureAlmost 90% of European patients who had relapsed after previous treatment with pegylated interferon and ribavirin were cured of hepatitis C after 24 weeks of treatment with the protease inhibitor simeprevir combined with pegylated interferon and ribavirin, the 49th Annual Meeting of the European Association for the Study of the Liver heard on Thursday in London. Full story at

Boehringer's Pradaxa gets FDA Approval for DVT, PE treatment

FDA ApprovedGermany-based pharmaceutical firm Boehringer Ingelheim has received approval from the U.S. Food and Drug Administration for Pradaxa to treat venous thromboembolism (VTE), which includes both deep venous thrombosis (DVT) and pulmonary embolism (PE). Full story at PBR

U.S. FDA Approves Biogen's Hemophilia B Drug Alprolix

Biogen Idec Inc. has won US. Approval for its long-acting hemophilia B treatment Alprolix. Canada approved the drug designed to extend the time between infusions for hemophiliacs who are missing factor IX proteins a week prior to the FDA approval. Full story at 



Baxter Acquires Chatham for $70M+, Boosting Its Hemophilia Pipeline

BaxterPicChicagoTribuneAp2014rz.jpgBaxter, an American health care company with over 60 years experience in developing hemophilia products, has purchased Chatham, a private biotechnology company developing treatments for hemophilia.

Full story at GEN News and Chicago Tribune


Canada OKs Biogen Idec drug for treatment of hemophilia B

Boston Globe

Canadian health officials have okayed a Biogen Idec Inc. drug that controls and prevents bleeding in patients with hemophilia B, marking the first approval of a new hemophilia treatment in nearly two decades and the entry of the Cambridge biotech into a market beyond multiple sclerosis medicines.

 Stroke in children will be focus of $3 million grant at CU
UCDenverGeneral MedicineResearchers at the University of Colorado Denver | Anschutz Medical Campus will receive a $3 million grant as part of a national effort to better understand stroke. The research, which will involve several researchers and doctors at the HTC, will be a collaboration with Children's Hospital Colorado, University of Colorado Hospital and the School of Medicine. Full story at

New Hemophilia Drugs Aim to Simplify Treatment


For 33-year-old video editor and hemophilia patient Travis Roop, being able to get life-saving infusions of a blood clotting agent every two weeks, instead of rushing to treat a bleeding episode, meant he could jog for the first time.

Full Story at


News Archives